EUVIMEDEUVIMED entdecken
Crossref

Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone

Hai-Lin Wu, Chao Xia, Fu-Sheng Liu, Bo-Yv Zheng, Hua-Qing Niu, Guo-Qiang Zhu, Ming-Xiang Zou, Bo-Wen Zheng iD

JCO Precision Oncology · 2024

DOI: 10.1200/po.24.00135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Hai-Lin Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Denosumab, Giant Cell Tumor of Bone, Bone Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The prognostic value of lymphocyte infiltration score (LIS) and its nearest neighbor distance to tumor cells (NNDTC) in giant cell tumor of bone (GCTB) is currently not well established. This study aims to characterize LIS and NNDTC and examine their correlation with denosumab treatment responsiveness, clinicopathologic features, and patient prognosis. METHODS Using multiplexed quantitative immunofluorescence, LIS was evaluated in 253 tumor specimens, whereas NNDTC was computed using HALO software. Subsequently, we analyzed the association of these parameters with patient outcomes (progression-free survival [PFS] and overall survival [OS]), clinicopathologic features, and denosumab treatment responsiveness. RESULTS Low LIS was indicative of both poor PFS and OS (both P < .001). In addition, LIS was significantly associated with sex ( P = .046), Enneking staging ( P < .001), Ki-67 expression ( P = .007), and denosumab treatment responsiveness ( P = .005). Lower CD8 + (tumor interior [TI]) NNDTC, and CD3 + (TI) NNDTC were associated with worse PFS ( P = .003 and .038, respectively), whereas lower CD8 + (TI) NNDTC was associated with worse OS ( P = .001), but CD8 + (tumor infiltrating margin) NNDTC had the opposite effect ( P = .002). Moreover, NNDTC showed a correlation with several clinicopathologic features. Importantly, LIS outperformed Enneking and Campanacci staging systems in predicting the clinical outcomes of GCTB. CONCLUSION These findings suggest that LIS is a reliable predictive tool for clinically relevant outcomes and response to denosumab therapy in patients with GCTB. These parameters may prove to be useful in guiding prognostic risk stratification and therapeutic optimization for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabGiant Cell Tumor of BoneBone NeoplasmsHumansMaleFemalePrognosisAdultMiddle AgedLymphocytes, Tumor-InfiltratingYoung AdultAdolescentBone Density Conservation AgentsAgedTreatment OutcomeRetrospective Studies

Substanzen

DenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Department of Spine Surgery, The First Affiliated Hospital, University of South China, Hengyang, China.
  • Department of Orthopedics Surgery, General Hospital of the Central Theater Command, Wuhan, China.
  • Department of Ophthalmology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Orthopedics Surgery, Xiangya Hospital, Central South University, Changsha, China.
  • Musculoskeletal Tumor Center, Peking University People's Hospital, Peking University, Beijing, China.

ORCID-Profile: Bo-Wen Zheng

Zitieren

APA

Wu, H. L., Xia, C., Liu, F. S., Zheng, B. Y., Niu, H. Q., Zhu, G. Q., Zou, M. X., & Zheng, B. W. (2024). Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone. JCO Precision Oncology. https://doi.org/10.1200/po.24.00135

Vancouver

Wu HL, Xia C, Liu FS, Zheng BY, Niu HQ, Zhu GQ, et al. Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone. JCO Precision Oncology. 2024. doi:10.1200/po.24.00135

BibTeX
@article{Wu2024,
  author = {Wu, Hai-Lin and Xia, Chao and Liu, Fu-Sheng and Zheng, Bo-Yv and Niu, Hua-Qing and Zhu, Guo-Qiang and Zou, Ming-Xiang and Zheng, Bo-Wen},
  title = {Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.24.00135}
}
Kostenlos starten →